FBN1 and obesity disorder: Asprosin deficiency may lead to loss of appetite and extreme leanness.[22] Diminished asprosin activity or asprosin depletion could be an innovative therapeutic modality for the treatment of T2DM and obesity, thus a potential target for diabetes treatment.[23]